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Our recent data demonstrate that activation of pmKATP channels polarizes the membrane of 
cardiomyocytes and reduces Na+/Ca2+ exchange-mediated Ca2+ overload. However, it is 
important that these findings be extended into contractile models of hypoxia/reoxygenation 
injury to further test the notion that pmKATP channel activation affords protection against 
contractile dysfunction and calcium overload. Single rat heart right ventricular myocytes were 
enzymatically isolated, and cell contractility and Ca2+ transients in field-stimulated myocytes 
were measured in a cellular model of metabolic inhibition and reoxygenation. Activation of 
pmKATP with P-1075 (5 µM) or inhibition of the Na+/Ca2+ exchanger with KB-R7943 (5 µM) 
reduced reoxygenation-induced diastolic Ca2+ overload and improved the rate and magnitude of 
posthypoxic contractile recovery during the first few minutes of reoxygenation. Moreover, 
diastolic Ca2+ overload and posthypoxic contractile dysfunction were aggravated in ventricular 
myocytes either subjected to specific blockade of pmKATP with HMR1098 (20 µM) or expressing 
the dominant-negative pmKATP construct Kir6.2(AAA) in the presence of P-1075. Our results 
suggest that a common mechanism, involving resting membrane potential-modulated increases 
in diastolic [Ca2+]i, is responsible for the development of contractile dysfunction during 
reoxygenation following metabolic inhibition. This novel and highly plausible cellular 
mechanism for pmKATP-mediated cardioprotection may have direct clinical relevance as 
evidenced by the following findings: a hypokalemic polarizing cardioplegia solution 
supplemented with the pmKATP opener P-1075 improved Ca2+ homeostasis and recovery of 
function compared with hyperkalemic depolarizing St. Thomas’ cardioplegia following 
contractile arrest in single ventricular myocytes and working rat hearts. We therefore propose 
that activation of pmKATP channels improves posthypoxic cardiac function via reductions in 
abnormal diastolic Ca2+ homeostasis mediated by reverse-mode Na+/Ca2+ exchange. 
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ince the discovery of plasma-membrane (pm) KATP channels in cardiac myocytes 21 years 
ago (1), these channels have been shown to be important in the control of cardiac 
excitability during ischemic episodes, and many studies have demonstrated that activation 
of pmKATP channels under hypoxic or ischemic conditions is cardioprotective (2–5). PmKATP 
channels have also been implicated in the powerful cardioprotective phenomenon of ischemic 
preconditioning (IPC) (6, 7). 
Initially, it was thought that the negative inotropy caused by pmKATP channel-mediated action 
potential shortening would conserve energy and be protective, but this was challenged by the 
finding that KATP channel openers protected the heart in concentrations that did not shorten the 
cardiac action potential (8, 9). Subsequently, another distinct population of KATP channels found 
in the inner mitochondrial membrane (mitoKATP) was suggested as an important mediator of the 
cardioprotective effects of KATP channel openers (10–13). However, our own recent work (14), 
in which we used electrically quiescent myocytes and still observed pmKATP-mediated protection 
in the absence of any action potential generation, suggests that pmKATP channel activation can be 
protective via a mechanism other than action potential shortening. Recent transgenic animal 
experiments have provided strong evidence that activation of pmKATP channels is a major player 
in the observed cardioprotection. For example, the hearts from pmKATP channel knockout mice 
failed to precondition and had poor postischemic functional recovery—an effect mimicked in 
wild-type mice by the pmKATP channel selective inhibitor HMR1098 (15). From the available 
evidence, it is likely that activation of both pm and mitoKATP channels can be protective via 
distinct mechanisms and have central roles to play in IPC and cardioprotection (5). 
It is perhaps difficult to reconcile the purpose of pmKATP channels, despite their high density, if 
they have no role to play during periods of metabolic stress such as intense exercise or ischemia. 
Clearly this is not the case, as there is excellent evidence to support the protective effects of 
pmKATP channel activation in the ischemic myocardium. Therefore, a separate and as yet 
unidentified pmKATP channel-mediated protective mechanism likely exists. In this regard, recent 
evidence from our and other laboratories suggests that Ca2+ handling is regulated by pmKATP 
channel activity (14, 16–18). 
One of the major clinical correlates of ischemia/reperfusion injury is contractile dysfunction, in 
which Ca2+ overload via increased Na+/Ca2+ exchange is a major contributor (19, 20). Based on 
our recent data (21, 14), we postulated that a major function of pmKATP channels is to favor a 
polarized membrane potential and therefore reduce the magnitude of reverse-mode Na+/Ca2+ 
exchange decreasing intracellular Ca2+ overload during periods of metabolic stress such as 
ischemia/reperfusion or intense cardiac work. This would diminish the likelihood of cellular 
injury such as hypercontracture/death and contractile stunning (22) or the development of 
arrhythmias. 
In this present study, we investigate the relationship between pmKATP activation, reverse-mode 
Na+/Ca2+ exchanger activity, intracellular calcium transients, and contractile dysfunction during 
recovery following a brief period of metabolic inhibition in field-stimulated rat ventricular 
myocytes. In addition, we then investigate the implications of our initial findings in the setting of 
S 
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 experimental cardioplegia using hyperkalemic-depolarizing and hypokalemic-polarizing 
solutions in single-cell and whole-heart models. 
MATERIALS AND METHODS 
Myocyte isolation 
Adult male Sprague-Dawley rats were killed with pentobarbital (150 mg/kg, i.p.) according to 
the University of Alberta Animal Policy and Welfare Committee and the Canadian Council on 
Animal Care (CCAC) Guidelines. The hearts were then removed, and ventricular myocytes were 
obtained by enzymatic dissociation using the standard protocols described previously (23, 24). 
After 1 h, cells were placed on coverslips for observation at ×200 with an inverted microscope 
and were superfused with control solution containing (in mM): NaCl 140, KCl 5, HEPES 10, 
CaCl2 2.0, MgCl2 1.4, and glucose 10. 
Measurement of cell shortening and Ca2+ transients 
Cell shortening was measured using a video edge detector system (Crescent Electronics, Salt 
Lake City, UT) at 60 Hz frame rate. Myocytes were field-stimulated with 2 ms square pulses at a 
constant current 20% above threshold value. Cell shortening was expressed as fractional 
shortening (∆L/L0, where L0 is resting cell length). 
Ventricular myocytes from adult rats were loaded for 30 min at room temperature and for 30 min 
at 37°C with the Ca2+-sensitive fluorescent probe Calcium Green-1AM (4 µM, in a 1:1 v/v 
dimethyl sulfoxide:pluronic acid mixture, Molecular Probes, Eugene, OR). After loading, cells 
were washed and placed on coverslips for observation at ×200. Cells were then superfused as 
described above. A Photon Technology International Photomultiplier Detection System (PTI, 
Lawrenceville, NJ) with Clampex software (version 8.1) was used for data acquisition and 
analysis. Calcium Green-1AM was excited with 480 nm light, and the emitted light intensity at 
520 nm was digitized and stored. The duration of the Ca2+ transient at 90% recovery was 
obtained by measuring the interval between the onset of the Ca2+ transient (10% above the 
average diastolic value) to the time point where the transient returned to 90% of average diastolic 
value. Cell shortening and Ca2+ transient experiments were performed at room temperature 
(22±1°C). 
In vivo adenoviral cardiomyocyte infection with the dominant-negative Kir6.2(AAA) 
construct 
The dominant-negative triple point mutation GFG to AAA in the pore region of the KATP channel 
subunit Kir6.2 (24) was created using the protocol outlined in the QuikChange site-directed 
mutagenesis kit (Stratagene, La Jolla, CA). GFG→AAA, forward primer: 5′ 
caggtgagcattgctgccgccgggcgcatggtgac 3′; reverse, 5′ ccatgcgcccggcggcagcaatggtcacctgg 3′. The 
sequenced Kir6.2(AAA) insert was then excised from pCDNA3 vector and reinserted into 
pAdTrack-CMV transfer vector and the bicistronic adenoviral vector designed to coexpress 
Kir6.2(AAA), and GFP was then constructed as per the manufacturer’s instructions (PAdEasy, 
Stratagene). The bicistronic adenoviral design is illustrated in Fig. 3A. Cardiomyocytes were 
infected in vivo to overexpress either the green fluorescent protein (GFP) (control) or GFP in 
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 combination with Kir6.2(AAA). Following left lateral thoracotomy, a solution containing 4 × 
1011 pfu/ml viral titer (10 µl/injection site, 10 sites) was injected into the lateral left ventricular 
wall and into the apex of the heart. The animals were allowed to recover for 5 days, and then 
single ventricular myocytes were isolated from the infected region by visual identification of 
GFP expression. 
Measurement of whole-cell current in tsA201 cells expressing the rat NCX1.1 
Infection of tsA201 cells with 30 pfu/cell of an adenoviral rat heart NCX1.1 construct was 
performed, and whole-cell patch clamp recordings were undertaken as described previously (26). 
The NCX1.1 construct was generously provided by Dr. J. Lytton (University of Calgary, 
Calgary, Alberta, Canada) and the adenovirus construct by Dr. J. Y. Cheung (Geisinger Medical 
Center, Danville, PA) (27). 
Cardioplegia in isolated rat ventricular myocytes 
Isolated rat ventricular myocytes were subjected to the following protocol: 2 min with control, 4 
min with a cardioplegia solution (either St. Thomas’ cardioplegia [STC] or hyperpolarizing 
cardioplegia solution [HPC]), 6 min cardioplegia with metabolic inhibition (MI; 5 mM 2-deoxy-
glucose + 4 mM NaCN), and 12 min recovery with control solution. Table 1 shows the 
composition of solutions used in the cardioplegia experiments. All solutions had a pH of 7.4. 
Fractional cell shortening and Ca2+ transients were recorded continuously during the protocol as 
described above. 
Cardioplegia in perfused rat hearts 
Male Sprague-Dawley rats (300–350 g) were anesthetized with sodium pentobarbital, and their 
hearts were excised and perfused in Langendorff (nonworking) mode at a constant perfusion 
pressure of 60 mmHg with Krebs-Henseleit solution at 37°C for 10 min. Hearts were then 
randomly assigned to groups that received either 25 ml of ice-cold STC (n=8) or 25 ml of ice-
cold HPC (n=7) solution (Table 1) administered at constant perfusion pressure of 60 mmHg (Fig. 
7A). Hearts were then removed from the perfusion apparatus and stored in their respective 
cardioplegia solution at 3°C for 6 h. Following storage, hearts were rewarmed to 37°C during 10 
min of Langendorff mode perfusion. Recovery of mechanical function was assessed during a 
subsequent 30-min period of working mode during which perfusate entered the left atrium at a 
constant preload (11.5 mmHg) and was ejected by the left ventricle against a constant afterload 
(80 mmHg). A group of hearts that were perfused under identical conditions, but not subjected to 
cardioplegia or storage, served as nonstored controls (n=8). Coronary flow (ml/min) was 
measured during Langendorff perfusion periods before and after cardioplegia. During working 
mode perfusion, systolic and diastolic aortic pressures, cardiac output (CO), and aortic flow were 
measured. Left ventricular minute work (l/min.mmHg) was calculated as CO × (peak systolic 
pressure – preload pressure) as described previously (28) and served as an index of cardiac 
mechanical function. 
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 Drugs and chemicals 
HMR 1098 (1-[[5-[2-(5-chloro-o-anisamido)ethyl]-2-methoxyphenyl]sulfonyl]-3-methylthiourea, 
sodium salt) (Aventis, Frankfurt, Germany) was dissolved as a 5 mM stock solution in distilled water. 
KB-R7943 (Tocris, Ellisville) and P-1075 (Tocris) were made up as 10 and 20 mM stock solutions in 
dimethyl sulfoxide, respectively. Pluronic F-127 (Molecular Probes) was prepared as a 20% w/v stock 
solution in dimethyl sulfoxide. Each stock solution was diluted to the required concentration immediately 
before use. 
Statistics 
All data are presented as mean ± SE. Statistical analyses of data were performed using Student’s 
paired and unpaired t test and ANOVA as appropriate. A level of P < 0.05 was considered 
statistically different. 
RESULTS 
Activation of pmKATP and inhibition of the Na+/Ca2+ exchanger reduce the duration of post-
MI contractile dysfunction in rat ventricular myocytes 
Previous experiments have demonstrated that activation of pmKATP channels in electrically 
quiescent myocytes reduced Ca2+ loading and cellular hypercontracture during reoxygenation 
(14). However, in order to translate these findings to dynamic changes in contractility, a field-
stimulated working myocyte model was adopted. Reoxygenation of ventricular myocytes 
following 6 min of metabolic inhibition resulted in a transient decrease in contractile amplitude 
during reoxygenation (Fig. 1A). Myocytes reoxygenated with the pmKATP opener P-1075 (5 µM) 
(Fig. 1C), the Na+/Ca2+ exchanger inhibitor KB-R7943 (5 µM) (Fig. 1B), or their combination 
(Fig. 1D) exhibited a similar transient decrease in contractile amplitude. However, the duration 
of the decrease in contractile amplitude was significantly less in the P-1075 and KB-R7943 
groups compared with control (see Fig. 1E). The pmKATP inhibitor HMR 1098 (20 µM) blocked 
the effect of 5µM P-1075 on duration of dysfunction (Fig. 1E). When applied alone, HMR 1098 
did not increase the duration of dysfunction (Fig. 1E) but caused a significant reduction in 
contractile recovery at the end of the reoxygenation period (Fig. 1F). 
The contractile performance of isolated rat ventricular myocytes during baseline steady-state 
conditions and at 2 min of reoxygenation following MI is summarized in Fig. 2A–D. The 
myocyte cell length at basal conditions, ranging from 98.6 ± 10.0 to 112.7 ± 7.9 µm (Table 2) 
(mean=104.8±2.4 µm, n=47 cells), was not significantly different among groups. In addition, 
fractional cell shortening and ±dL/dt values at basal conditions were not significantly different 
among groups (Table 2). There was a reduction in fractional cell shortening and its first 
derivative (±dL/dt) in all groups at 2 min reoxygenation (Table 2). However, fractional cell 
shortening, maximum rate of shortening (+dL/dt), and maximum rate of relaxation (–dL/dt) were 
significantly higher in groups superfused with the pmKATP opener P-1075 (5 µM), Na+/Ca2+ 
exchanger inhibitor KB-R7943 (5 µM), and their combination, indicating improved contractility 
and relaxation at the early stages of reoxygenation in these groups (Table 2 and Fig. 2E). In 
myocytes reoxygenated with solutions containing the specific pmKATP inhibitor HMR 1098, 
fractional cell shortening and ±dL/dt values were similar to those of the control group but were 
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 significantly lower than in the P-1075 group at 2 min reoxygenation (Table 2 and Fig. 2E). The 
maximum rate of shortening and relaxation fully recovered by the end of the reoxygenation 
period in the control, P-1075, and KB-R7943 + P-1075 groups, but were significantly reduced in 
the HMR 1098, HMR 1098 + P-1075, and KB-R7943 groups (Table 2). These results confirm 
the protective effect of activation of pmKATP channels but also indicate that by the end of the 
reoxygenation period, when cardiac myocytes have recovered from metabolic inhibition, the 
blockade of the Na+/Ca2+ exchanger is no longer beneficial. Our data are in agreement with a 
recent study showing that KB-R7943 is cardioprotective but can also have negative inotropic 
effects (29). 
There were no significant differences in time to peak shortening (TPS) and duration of 
contraction values among the experimental groups in basal conditions and at 2 min 
reoxygenation (Table 2). In the KB-R7943 group, however, both TPS and the length of 
contraction were significantly longer than in the control group, indicating slower contractions 
during field stimulation (Table 2). 
Functional pmKATP channels are needed for improved recovery during early reoxygenation 
While these studies provide evidence for the protective role of pharmacological pmKATP channel 
activation with P-1075, it is necessary to confirm and extend these findings using a molecular 
approach to functionally silence endogenous pmKATP channel activity. The next set of 
experiments was performed with the specific aim of studying the cardioprotective efficacy of P-
1075 in the presence and absence of functional pmKATP channels during reoxygenation following 
metabolic inhibition. To achieve this, we constructed a dominant-negative adenoviral construct 
of the pmKATP channel subunit Kir6.2, AdVKir6.2(AAA), that also coexpresses GFP (30). 
Single-cell contractility experiments were performed on myocytes infected in vivo with 
AdVKir6.2(AAA) 96 h before enzymatic dissociation. This infection period is sufficient to allow 
incorporation of the mutated Kir6.2(AAA) subunit into the endogenous KATP channel complex 
and suppress functional KATP current (30). Visually identified ventricular myocytes (Fig. 3A) 
were then subjected to the previously described MI/reoxygenation protocol. There was no 
difference in basal cell length and fractional cell shortening between the AdVKir6.2(AAA)/P-
1075 and control groups (100.2±11.6 vs. 112.7±8.0 µm and 13.0±1.6 vs. 12.8±1.3%, 
respectively; P>0.05). However, after the development of reoxygenation-induced contractile 
dysfunction, myocytes expressing the Kir6.2(AAA) construct, in the presence of P-1075, failed 
to recover (Fig. 3B, 3C). Note that in the presence of nonfunctional pmKATP channels, P-1075 (5 
µM) did not offer any beneficial effects on contractile function in these myocytes in early 
reoxygenation. These results confirm a critical role of pmKATP in posthypoxic cardiac functional 
recovery and are in good agreement with the studies of Suzuki et al. (15) on Kir6.2 KO mouse 
hearts. 
Reduction of post-MI diastolic [Ca2+]i following pmKATP activation and inhibition of the 
Na+/Ca2+ exchanger: possible mechanism for the amelioration of contractile dysfunction 
Abnormal calcium homeostasis in the form of diastolic Ca2+ overload is a major contributor to 
the contractile and electrical dysfunction observed during reperfusion/reoxygenation (31). 
Reverse-mode Na+/Ca2+ exchange activity is thought to play an important role in the 
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 development of calcium overload (19, 20). Therefore, we set out to determine the effects of 
pmKATP channel activation and Na+/Ca2+ exchange inhibition on dynamic changes in 
intracellular calcium. 
Field-stimulated ventricular myocytes were subjected to the MI/reoxygenation protocol, and 
Ca2+ transients were continuously recorded every 1 s for the duration of the experiment. There 
was a substantial increase in diastolic [Ca2+]i during reoxygenation with the control solution, 
followed by a recovery to basal values (Fig. 4A). Application of the Na+/Ca2+ exchanger inhibitor 
KB-R7943 (5 µM), the pmKATP opener P-1075 (5 µM), and their combination in the 
reoxygenation solution significantly reduced elevations in [Ca2+]i (Fig. 4). The pmKATP inhibitor 
HMR 1098 prevented the beneficial effects of P-1075 on diastolic [Ca2+]i but did not cause a 
further increase when applied alone (Fig. 4E). These data are in agreement with our previous 
results from quiescent rat ventricular myocytes (14). The time course of changes in diastolic 
[Ca2+]i and development of contractile dysfunction were similar in the present study, suggesting 
a close relationship between diastolic Ca2+ levels and myocardial function in reoxygenation 
following metabolic inhibition. 
Detailed analysis revealed no significant differences in the duration of the Ca2+ transient at 90% 
recovery level, the time to peak, and the amplitude of the Ca2+ transients in any of the 
experimental groups in basal conditions and during reoxygenation (Table 3). These results 
suggest that in our cellular model of stunning, increases in diastolic [Ca2+]i and not alterations in 
calcium handling are responsible for the development of postischemic contractile dysfunction. 
To confirm the inhibitory effect of 5 µM KB-R7943 on reverse-mode Na+/Ca2+ exchange, some 
whole-cell patch-clamp experiments were carried out on tsA201 cells expressing rat heart 
NCX1.1. Large outward currents (due to reverse-mode Na+/Ca2+ exchanger activity) were 
recorded from these cells when a Ca2+-free extracellular solution was changed to a solution 
containing 2 mM Ca2+ at 0 mV holding potential as described previously (26). A representative 
trace from those experiments demonstrates that 5 µM KB-R7943 almost completely inhibited 
this outward current (Fig. 4F). 
Diastolic resting membrane potential of ventricular myocytes is critically important in the 
recovery of function and calcium homeostasis during simulated cardioplegia 
Postoperative cardiac dysfunction is a common problem associated with the use of hyperkalemic 
cardioplegic solutions (32, 33). Our data suggest that maneuvers designed to hyperpolarize the 
resting membrane potential of cardiomyocytes may afford a marked degree of protection from 
ischemia/reperfusion injury in the setting of cardioplegia. Therefore, we compared the 
contractility of cardiac myocytes subjected to cardioplegia with modified depolarizing STC 
solution (containing 16 mM K+) and an HPC solution (containing 3.2 mM K+). During 
superfusion with STC, in some ventricular myocytes large contractions were observed, this 
behavior was not detected in cells in the HPC group (Fig. 5A, 5B). The improved recovery of 
function (∆L and dL/dt) in the HPC group compared with the STC group is illustrated in Fig. 5A 
and 5B. Fractional cell shortening was significantly better at 6 and 12 min of recovery following 
cardioplegia in the HPC group compared with STC (Fig. 5C). Diastolic cell length was 
significantly reduced in the STC group and was significantly increased in the HPC group 
compared with basal values in the same group. Diastolic cell length was also significantly shorter 
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 in the STC group compared with HPC during cardioplegia + MI and did not return to basal cell 
length as opposed to the HPC group (Fig. 5D). 
Calcium transients were recorded from another two groups of ventricular myocytes subjected to 
the same cardioplegia protocol, with either STC or HPC. Representative recordings show Ca2+ 
transients from two myocytes from the STC and the HPC groups in Fig. 6A and 6B, respectively. 
Note the increase in diastolic [Ca2+]i during recovery following STC and lack of change in 
diastolic [Ca2+]i in recovery following HPC. Grouped data show that superfusion of ventricular 
myocytes with a depolarizing cardioplegia solution and subsequent metabolic inhibition resulted 
in a significantly elevated diastolic [Ca2+]i during recovery (Fig. 6D). These data further suggest 
a crucial role for resting membrane potential in the modulation of diastolic [Ca2+]i and 
cardiomyocyte function during recovery following cardioplegia. These results are also in 
agreement with our previous observations showing a close relationship between [K+]o, resting 
membrane potential, and Na+/Ca2+ exchanger-mediated Ca2+ loading (21). 
HPC with activation of pmKATP improves cardiac function in isolated working rat hearts 
To determine whether the beneficial effects of the HPC solution on Ca2+ homeostasis of 
ventricular myocytes directly translates into improved cardiac recovery, we carried out another 
series of experiments on isolated rat hearts. Hearts were randomly assigned to three groups: 1) 6 
h of depolarizing cardioplegia with STC solution, 2) 6 h of hyperpolarizing cardioplegia with 
HPC solution, and 3) a group of hearts not subjected to cold cardioplegic storage with a time-
matched recovery perfusion protocol of 10 min Langendorff and 30 min of working heart mode 
(Fig. 7A). Coronary artery flow significantly improved in the HPC group compared with the STC 
group at 10 min Langendorff perfusion following 6 h of cardioplegia (Fig. 7B). After 30 min of 
perfusion in working heart mode, cardiac function of rat hearts subjected to 6 h of STC was 
significantly impaired compared with both the HPC group and the control group not subjected to 
cold cardioplegic storage (Fig. 7C). Note that these experiments did not include subjecting the 
heart to metabolic inhibition and showed a similarly more beneficial effect of HPC on cardiac 
function compared with STC as observed in the single-cell model. 
DISCUSSION 
Overview 
In the present study, we confirm that activation of pmKATP channels is cardioprotective in a 
cellular model of contractility: addition of the pmKATP opener P-1075 to the reoxygenation 
solution 1) significantly reduced the duration of post-MI contractile dysfunction (Fig. 1) and 2) 
improved contractility (±dL/dt) during the period of dysfunction (Fig. 2). These effects were 
prevented by the selective pmKATP blocker HMR 1098 (Fig. 1, 2) and did not develop when 
ventricular myocytes expressing the dominant-negative Kir6.2(AAA) pmKATP construct were 
superfused with P-1075-containing solution (Fig. 3). Our results show that improved Ca2+ 
homeostasis is responsible for the beneficial effects of pmKATP channel activation in early 
reoxygenation. Specifically, activation of pmKATP reduced the increase in diastolic [Ca2+]i during 
reoxygenation (Fig. 4C–E). This effect could be reversed by adding the pmKATP inhibitor HMR 
1098 to the reoxygenation solution, resulting in a diastolic [Ca2+]i increase similar to the control 
group (Fig. 4E). 
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 pmKATP channel pharmacology 
The purpose of this study was to investigate whether activation of pmKATP channels can improve 
contractile function and Ca2+ homeostasis after metabolic inhibition/reoxygenation and 
experimental cardioplegia. Therefore, it was necessary to selectively activate and block pmKATP 
as opposed to mitoKATP channels. Functional KATP channels are formed by four inwardly 
rectifying potassium channel subunits (Kir6.2) and four regulatory sulphonylurea receptor 
subunits (SUR) (34). The distinct isoforms of SUR expressed in different tissues confer 
pharmacological characteristics to KATP channels, and SUR2A is the isoform found in the plasma 
membrane of cardiac myocytes (35). The pmKATP channel has been identified as Kir6.2/SUR2A, 
while the pharmacological profile of the mitoKATP is very similar to Kir6.1/SUR1 (36). In the 
present experiments, the pinacidil derivative P-1075 was used for pmKATP channel activation 
(36) and the cardioselective sulphonylurea HMR 1098 was used for inhibition of pmKATP 
channels (37). Recent work from our laboratory shows that HMR 1098 is a selective inhibitor of 
Kir6.2/SUR2A and has no effect on the strong inward rectifier Kir2.1 current (38). 
Previous studies on guinea pig ventricular myocytes and canine Purkinje fibers have reported a 
strong action potential duration (APD) shortening effect of P-1075 at micromolar concentrations 
(39, 40). In a set of preliminary experiments on normoxic rat ventricular myocytes, a 10 min 
superfusion of 5 µM P-1075 caused a significant outward current in whole-cell perforated patch 
recordings as well as a mild negative inotropic effect (data not shown). These initial findings are 
in agreement with the data in Table 2 and suggest a relatively smaller reduction in APD in rat 
ventricular myocytes as opposed to species with a longer APD possessing pronounced plateaus. 
We have previously shown that the KATP opener cromakalim (50 µM) has minimal effects on the 
rat ventricular myocyte APD (24, 41). However, when chronic disease states (diabetes and 
hypothyroidism) are induced and a significant increase in APD is observed, cromakalim has a 
much greater APD shortening effect (24, 41). These data suggest that 5 µM P-1075 affects APD 
in rat ventricular myocytes, although certainly not enough to severely impair contractility. 
P-1075 had no beneficial effect on contractile recovery in ventricular myocytes expressing the 
dominant-negative Kir6.2(AAA) pmKATP construct (Fig. 3) as opposed to those expressing the 
endogenous wild-type pmKATP channel (Fig. 1, 2). These results suggest that the effects of P-
1075 and HMR 1098 observed during reoxygenation are linked to pmKATP and not to mitoKATP. 
The suggestion that only activation of mitoKATP as opposed to pmKATP results in protection of 
the myocardium (10) is largely based on pharmacological studies using diazoxide for opening 
and 5-hydroxydecanoate (5-HD) for blocking mitoKATP channels (11, 12). Diazoxide has been 
shown to 1) cause flavoprotein oxidation independent of mitoKATP effects (42, 43); 2) activate 
pmKATP channels even at low concentrations in the presence of ADP, which is likely to be 
present in ischemia and early reperfusion (44); and 3) protect the myocardium without 
depolarizing mitochondria or oxidizing flavoproteins (45). 5-HD can be a substrate or inhibitor 
of fatty acid β-oxidation (46, 47), opposing its use as a specific mitoKATP inhibitor. 
We and others suggest that activation of both subpopulations of KATP channels have important 
cardioprotective effects (5, 10). Several papers published recently provide evidence that pmKATP 
has a critical role in protecting the myocardium in ischemia/reperfusion experiments. The well-
characterized infarct size decreasing effect of ischemic preconditioning was abolished in Kir6.2-
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 deficient mice, and this result could be reproduced by specific blockade of pmKATP channels in 
their wild-type counterparts (15). Recently, diazoxide has been shown to exert its 
cardioprotective effects only in mice hearts expressing pmKATP channels, not in Kir6.2 knockout 
hearts (48). These studies strongly support a critical cardioprotective role for pmKATP channels in 
the setting of ischemia/reperfusion. To date, however, researchers have not identified the precise 
ionic mechanisms responsible for this protection. 
Intracellular mechanisms for pmKATP channel-mediated protection 
Ischemia and subsequent reperfusion of the heart can cause elevated [Ca2+]i in ventricular 
myocytes leading to 1) the development of cardiac arrhythmias and sudden cardiac death; 2) 
reversible contractile dysfunction and myocardial stunning (31); 3) the opening of the 
mitochondrial permeability transition pore, mitochondrial swelling, and eventually cell necrosis; 
and 4) apoptosis (49). Therefore, strategies that decrease pathological increases in [Ca2+]i in 
ventricular myocytes potentially reduce reversible and irreversible myocyte injury and result in 
improved survival and function of the myocardium. The mechanism by which altered calcium 
homeostasis causes contractile dysfunction is still not clearly established. Calcium can activate 
proteases (e.g., calpain I) which in turn modifies the Ca2+ sensitivity or degradation of 
myofilaments, such as troponin I (50). It has also been shown that a species-dependent altered 
Ca2+ handling can significantly contribute to postischemic dysfunction (51). Our results confirm 
that increased [Ca2+]i causes contractile dysfunction in reoxygenation following a brief period of 
metabolic inhibition. In the present study, no significant differences were detected in the 
duration, amplitude, and time to peak of the calcium transient in the test groups compared with 
the control group during reoxygenation (Table 3), suggesting that instead of altered calcium 
handling, increased basal diastolic [Ca2+]i plays a critical role in the development of contractile 
dysfunction in our experimental model. 
The Na+/Ca2+ exchanger is a major regulator of intracellular calcium homeostasis in cardiac 
myocytes, with the primary function of removing Ca2+ from the cytosol during diastole, and it 
can also play a significant role in excitation-contraction coupling (52). However, the exchanger 
can be a significant contributor to increased [Ca2+]i during hypoxia/reoxygenation (20), when the 
elevated [Na+]i and depolarization of the plasma membrane (21) can cause the exchanger to work 
in reverse mode. Accordingly, antisense inhibition (19) or pharmacological block (21) (Fig. 1G, 
Fig. 4B, 4E) of the Na+/Ca2+ exchanger decreases reoxygenation-induced calcium overload in 
ventricular myocytes. The results from this present study (Fig. 1, 2, and 4) further confirm a 
central role for reverse-mode Na+/Ca2+ exchanger activity in elevating diastolic [Ca2+]i and 
causing contractile dysfunction in ventricular myocytes after a metabolic insult. 
In two recent studies using quiescent rat ventricular myocytes, we have shown that calcium 
overload via reverse-mode Na+/Ca2+ exchanger activity is critically dependent on diastolic 
membrane potential (21) and that pharmacological activation of pmKATP channels causes 
hyperpolarization of the diastolic membrane potential and prevents calcium overload (14). Based 
on the findings of these previous studies and the results of the present experiments, we conclude 
that 1) depolarization of the diastolic membrane potential, either in the setting of myocardial 
ischemia/reperfusion or by depolarizing cardioplegia, leads to increased diastolic [Ca2+]i and 
contractile dysfunction and 2) the activation of pmKATP channels protects the myocardium by 
hyperpolarization of the diastolic membrane potential that leads to the reduction of calcium 
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 overload and contractile dysfunction via membrane potential-dependent reverse-mode Na+/Ca2+ 
exchanger activity. 
Implications for cardioplegia 
During cardiac surgery, the heart is subjected to global ischemia. Many cardioplegic solutions 
used to arrest the heart in an attempt to preserve its function are hyperkalemic and contain >15 
mM [K+]. Although these solutions are generally effective, several studies suggest that the 
observed postoperative cardiac dysfunction observed in higher-risk patients can be due to, at 
least in part, the use of elevated [K+] (32, 33). Our results from isolated ventricular myocytes and 
working rat hearts provide evidence that the use of a hyperkalemic cardioplegic solution leads to 
inferior contractile function upon recovery compared with a hypokalemic solution.  
New strategies have been tested to reduce cardiac dysfunction following cardioplegia, including 
the addition of KATP channel openers to the arresting solutions, yielding inconsistent results. 
While the nonspecific KATP opener pinacidil has been found to enhance cardioprotection (53, 
54), lemakalim lost its ability to improve postischemic recovery when added to a hyperkalemic 
cardioplegic solution (55). Based on our findings, it is likely that lemakalim’s beneficial effects 
on cardiac function were diminished by membrane depolarization in the hyperkalemic milieu, as 
opening of KATP channels in this setting would merely clamp the resting membrane potential to a 
depolarized Nernst potential for potassium ions.  
We demonstrate here that an HPC solution supplemented with a specific pmKATP opener offers 
superior postischemic recovery compared with a depolarizing, hyperkalemic cardioplegia 
solution both in isolated ventricular myocytes (Fig. 5) and working rat hearts (Fig. 7). Our recent 
study indicates that increased [K+] depolarizes myocytes, leading to calcium overload due to 
reverse-mode Na+/Ca2+ exchange activity (21). Our findings confirm that solutions that 
hyperpolarize the diastolic membrane potential are effective during cardioplegia (56) and infer a 
mechanism for membrane potential-dependent changes in myocyte contractility as diastolic 
[Ca2+]i is increased when the membrane potential is depolarized in ventricular myocytes (Fig. 6). 
The present study is also in good agreement with a recent study showing impaired contractile 
function following depolarizing cardioplegia compared with hyperpolarizing cardioplegia with 
adenosine and lidocaine in rat hearts (57).  
Kobayashi et al. (58) have recently shown that a cardioplegia solution containing nicorandil 
provided significantly better myocardial oxygen consumption during recovery compared with a 
cardioplegia solution with 30 mM KCl. The present study and previous work from our laboratory 
(14, 21) provide evidence that reverse-mode Na+/Ca2+ exchanger activity is involved in resting 
membrane potential depolarization-induced increases in diastolic [Ca2+]i of ventricular myocytes 
and leads to the development of impaired contractile recovery after cardiac arrest with solutions 
containing elevated [K+]. 
Summary 
The results of the present study show that activation of pmKATP channels and inhibition of the 
Na+/Ca2+ exchanger reduces the duration of contractile dysfunction upon reoxygenation 
following metabolic inhibition. This pmKATP channel-mediated mechanism involves 
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 hyperpolarization of the resting membrane potential and a consequent reduction in Na+/Ca2+ 
exchanger-mediated elevation of diastolic [Ca2+]i. We propose that it is a novel and plausible 
mechanism by which activation of pmKATP offers cardioprotection against reperfusion injury and 
has direct clinical relevance in the setting of cardioplegia. 
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Table 1 
 
Composition of modified St. Thomas’ cardoplegia (STC) and hyperpolarizing cardioplegia (HPC) 
solutions (in mM) 
   STC  HPC  
 KCl   16  3.2  
 MgCl2  16  1  
 P-1075  not present  0.05  
 NaCl  110  140  
 CaCl2  2  2  
 HEPES  10  10  
 Glucose  10  10  
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Table 2 
 
Cardiomyocyte contractile function after MI/reoxygenationa 
    Reoxygenation 
  n Basal 2 min 10 min 
Diastolic cell Control 7 112.7  ±  8.0 110.1 ± 9.1 109.3 ± 8.5 
length (µm) KB-R 8 109.4 ± 3.8 108.1 ± 3.5 106.2 ± 3.4 
 P-1075 8 98.9 ± 4.0 99.8 ± 4.2 99.9 ± 4.3 
 KB-R + P-1075 7 98.6 ± 10.0 92.6 ± 9.94 94.2 ± 9.8 
 HMR 7 104.6 ± 4.5 92.7 ± 3.2 87.3 ± 5.9* 
 HMR + P-1075 10 108.2 ± 3.8 103.7 ± 7.3 103.2 ± 4.9 
      
Cell shortening Control 7 12.8 ± 1.3 1.3 ± 0.6 11.5 ± 1.8 
(%) KB-R 8 11.5 ± 0.8 6 ± 1.5* 7.3 ± 1.0 
 P-1075 8 11.7 ± 0.7 5.8 ± 1.4* 8.7 ± 1.0 
 KB-R + P-1075 7 13.9 ± 1.4 8.4 ± 2.0** 11.9 ± 1.4 
 HMR 7 14.7 ± 1.6 2.2 ± 1.5 6.2 ± 2.5* 
 HMR + P-1075 10 12.8 ± 1.0 2.7 ± 1.1 6.9 ± 1.3* 
      
Maximum rate of Control 7 171 ± 18.4 24 ± 8.3 151 ± 24.2 
shortening  KB-R 8 141 ± 16.7 80 ± 19.4 81 ± 14.6* 
(+dL/dt) P-1075 8 151 ± 17.3 85 ± 21.4 110 ± 23.4 
 KB-R + P-1075 7 172 ± 11.1 95 ± 19.2 123 ± 15.2 
 HMR 7 188 ± 19.2 16 ± 14.4# 60 ± 23.7* 
 HMR + P-1075 10 148 ± 13.6 34 ± 13.3# 86 ± 14.4* 
      
Maximum rate of Control 7 142 ± 15.5 15 ± 5.1 119 ± 21.7 
relengthening KB-R 8 113 ± 16.4 76 ± 19.8* 57 ± 12.4* 
(–dL/dt) P-1075 8 121 ± 20.7 68 ± 19.5* 79 ± 23.6 
 KB-R + P-1075 7 159 ± 13.5 82 ± 15.6* 104 ± 17.3 
 HMR 7 145 ± 17.7 12 ± 11.1# 43 ± 15.8* 
 HMR + P-1075 10 113 ± 12.7 24 ± 10.7# 55 ± 13.7* 
      
TPS (ms) Control 7 165.1 ± 9.8 111.9 ± 14.6 162.2 ± 6.3 
 KB-R 8 177.3 ± 11.0 180.1 ± 22.2 239.7 ± 8.2*** 
 P-1075 8 182.4 ± 17.2 157.3 ± 15.3 174.4 ± 14.1 
 KB-R + P-1075 7 156.8 ± 7.4 129.2 ± 6.6 186.7 ± 11.4 
 HMR 7 183.7 ± 7.8 168.5 ± 51.9 180.3 ± 12.3 
 HMR + P-1075 10 185 ± 6.5 150.2 ± 13.6 180.1 ± 5.8 
      
Contraction Control 7 313.1 ± 20.2 401.5 ± 30.8 338.8 ± 41.0 
length, 90% (ms) KB-R 8 391.8 ± 29.5 458.6 ± 64.9 531.7 ± 43.7* 
 P-1075 8 389.7 ± 47.5 397.5 ± 29.9 415.5 ± 41.1 
 KB-R + P-1075 7 340 ± 13.6 359.4 ± 32.2 400.8 ± 22.2 
 HMR 7 376.3 ± 21.9 468.1 ± 69.6 444 ± 73.9 
 HMR + P-1075 10 396.9 ± 23.6 409.3 ± 40.0 478.7 ± 50.2 
 
aKB-R, KB-R7943; HMR, HMR 1098; *P < 0.05, **P < 0.01, ***P < 0.001 vs. control, #P < 0.05 vs. P-1075 group. 
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Table 3 
 
TABLE 3. Properties of [Ca2+]i transients in cardiomyocytes after MI/reoxygenation 
    Reoxygenation 
  n Basal 2 min 10 min 
CaT90 (ms) Control 9 539±31.3 587±54.0 524±18.8 
 KB-R 11 511±16.4 512±28.5 546±28.5 
 P-1075 11 567±17.4 574±26.1 556±15.3 
 KB-R + P-1075 8 563±20.5 543±18.1 524±12.4 
 HMR 6 526±35.8 649±89.5 576±39.7 
 HMR + P-1075 7 542±14.7 727±142.2 554±10.2 
      
Time to peak Control 9 119±11.0 132±6.5 110±6.8 
(ms) KB-R 11 112±4.5 106±5.3 123±7.4 
 P-1075 11 117±8.5 117±7.3 103±5.1 
 KB-R + P-1075 8 106±5 109±6.9 104±5.0 
 HMR 6 98±7.3 159±62.9 159±65.0 
 HMR + P-1075 7 125±5.4 212±77.0 119±3.8 
      
Amplitude Control 9 100 64.3±13.2 93±8.1 
(% of basal) KB-R 11 100 93.9±11.3 94±4.1 
 P-1075 11 100 64.6±9.8 85±7.1 
 KB-R + P-1075 8 100 86±12.2 86.5±4.5 
 HMR 6 100 87.7±19.0 93.3±8.0 
 HMR + P-1075 7 100 53±8.6 90.8±7.2 
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Figure 1. Representative cell shortening recordings from field-stimulated (1 Hz) rat ventricular myocytes subjected to 2 
min of superfusion with control solution (basal), 6 min metabolic inhibition (MI), and 10 min reoxygenation with solution 
containing control vehicle (0.05% DMSO) (A), KB-R7943 (5 µM) (B), P-1075 (5 µM) (C), and P-1075 (5 µM) + KB-
R7943 (5 µM) (D). E) Grouped data show that inhibition of the Na+/Ca2+ exchanger (KB-R7943) as well as activation of 
pmKATP channels (P-1075) decrease the duration of post MI contractile dysfunction. F) Significant impairment of cell 
shortening was observed in cardiac myocytes superfused with the pmKATP channel blocker HMR 1098 at the end of the 
recovery period. ∆L (%): % change in cell length. A, B) Arrows denote duration of post-MI contractile dysfunction. A) 
Horizontal bar represents a 1 min interval. The duration of dysfunction was defined as the time period when the cell 
exhibited <50% of basal fractional cell shortening value in the reoxygenation period. n = 7–10 cells/group, **P < 0.01, 
***P < 0.001 vs. control group. 
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Fig. 2 
 
      
Figure 2. Pharmacological activation of pmKATP channels and inhibition of the Na+/Ca2+ exchanger improve contractility 
of rat ventricular myocytes during early reoxygenation following metabolic inhibition (MI). Representative traces show 
changes in cell length (∆L) and its first derivative (dL/dt) at the end of basal conditions and during contractile dysfunction 
in ventricular myocytes superfused with solution containing control vehicle (0.05% DMSO) (A), KB-R7943 (5 µM) (B), 
P-1075 (5 µM) (C), and KB-R7943 (5 µM) + P-1075 (5 µM) (D). E) Grouped data show maximal rate of shortening and 
relengthening (±dL/dt) at 2 min reoxygenation following MI. n = 7–10 cells/group, *P < 0.05 vs. control group, #P < 0.05 
vs. P-1075 group. 
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Figure 3. A) Bicistronic adenoviral vector design and image of a GFP-tagged rat ventricular myocyte 96 h after in vivo 
infection with the dominant-negative Kir6.2(AAA) pmKATP channel adenoviral construct. B) Representative cell 
shortening recording from a cardiac myocyte with the Kir6.2(AAA) construct subjected to 6 min metabolic inhibition 
(MI) and 10 min reoxygenation with control solution containing P-1075 (5 µM). C) Expanded cell shortening traces and 
their first derivative as well as grouped data show that in cardiac myocytes with the Kir6.2(AAA) construct the pmKATP 
opener P-1075 failed to reduce the duration of post-MI contractile dysfunction and recovery of function was impaired. n = 
4–7 cells/group, *P < 0 .05, **P < 0.01 vs. control group. 
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Figure 4. Representative Ca2+ transient recordings from field-stimulated (1 Hz) rat ventricular myocytes subjected to 6 
min metabolic inhibition (MI) and 10 min reoxygenation with solution containing control vehicle (0.05% DMSO) (A), 
KB-R7943 (5 µM) (B), P-1075 (5 µM) (C), and P-1075 (5 µM) + KB-R7943 (5 µM) (D). Expanded Ca2+ transient traces 
were taken from the end of control (i), during peak dysfunction (ii), and at the end of reoxygenation periods (iii). E) 
Grouped data show significant reduction of reoxygenation-induced maximum increases in diastolic Ca2+ after activation 
of pmKATP channels (P-1075) as well as inhibition of the Na+/Ca2+ exchanger (KB-R7943). F) Representative trace from a 
tsA201 cell expressing rat heart NCX1.1 shows block of NCX1.1 outward current by 5 µM KB-R7943 in a whole-cell 
patch-clamp configuration at a holding potential of 0 mV. Drugs were added to the reoxygenation solution only. A) 
Horizontal bars represent 1 min and 1 s intervals, respectively. Maximum increase in diastolic [Ca2+]i was normalized to 
the amplitude of the Ca2+ transient at the end of control period in each cell. n = 7–11 cells/group, **P < 0.01 vs. control 
group, #P < 0.05 vs. HMR 1098 group. 
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Figure 5. Representative cell shortening recordings from field-stimulated rat ventricular myocytes superfused with 
depolarizing St. Thomas’ cardioplegia (STC), metabolic inhibition (MI), and reoxygenation solutions (A) and with 
hyperpolarizing cardioplegia (HPC), MI, and reoxygenation solutions (B). Myocytes in both groups were superfused with 
control solution during the recovery period. Cardiomyocytes in the STC group exhibited occasional large contractions 
during superfusion with the cardioplegia solution. This behavior was not observed in the HPC group. Note the improved 
post-MI contractile recovery in the HPC group (B) compared with the reduced contractility and rate of relaxation in the 
STC group (A) as demonstrated by individual cell shortening, rate of cell shortening traces (averaged for 10 steady-state 
beats), and grouped data (C). D) Diastolic cell length was significantly shorter in the STC group during cardioplegia + MI 
and at the end of the 12 min recovery periods. In the HPC group, diastolic cell length significantly increased during 
cardioplegia + MI and returned to control by the end of the recovery period. A, B) Arrows indicate time points where cell 
shortening traces were used to construct individual traces. n = 7 in all groups, *P < 0.05 vs. STC group. # #P < 0.01, and # # 
#P < 0.001 vs. control period in the same group. 
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Figure 6. Representative Ca2+ transient recordings from field-stimulated rat ventricular myocytes superfused with St. 
Thomas’ cardioplegia (STC) (A) or hyperpolarizing cardioplegia (HPC) (B) solutions before and during metabolic 
inhibition (MI). A marked increase in diastolic [Ca2+]i was observed in myocytes superfused with STC during recovery as 
demonstrated by the full 24 min recordings (A, B), individual Ca2+ transients (C), and grouped data (D). Arrows denote 
time points where individual Ca2+ transients were used to construct panel C. n = 8 cells in all groups. *P < 0.05 vs. STC 
group. 
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Figure 7. A) Heart perfusion protocol. Rat hearts underwent an initial 10 min Langendorff perfusion then were subjected 
to 6 h St. Thomas’ cardoplegia (STC) or hyperpolarizing cardioplegia (HPC) and 10 min Langendorff reperfusion followed 
by 30 min working mode reperfusion. Grouped data show significantly increased coronary artery flow at 10 min recovery 
in the HPC group compared with the STC group (during Langendorff mode) (B), and significantly improved left 
ventricular (LV) work in the HPC group at the end of 30 min recovery period in working heart configuration (n=7–8 
hearts/group) (C). *P < 0.05 vs. STC group.  #P < 0.05 vs. control group. 
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